keyword
MENU ▼
Read by QxMD icon Read
search

duloxetine pain

keyword
https://www.readbyqxmd.com/read/28919811/response-to-duloxetine-in-chronic-low-back-pain-exploratory-post-hoc-analysis-of-a-japanese-phase-iii-randomized-study
#1
Toshinaga Tsuji, Naohiro Itoh, Mitsuhiro Ishida, Toshimitsu Ochiai, Shinichi Konno
PURPOSE: Duloxetine is efficacious for chronic low back pain (CLBP). This post hoc analysis of a Japanese randomized, placebo-controlled trial (ClinicalTrials.gov, NCT01855919) assessed whether patients with CLBP with early pain reduction or treatment-related adverse events of special interest (TR-AESIs; nausea, somnolence, constipation) have enhanced responses to duloxetine. PATIENTS AND METHODS: Patients (N = 456) with CLBP for ≥6 months and Brief Pain Inventory (BPI) average pain severity score of ≥4 were randomized (1:1) to duloxetine 60 mg/day or placebo for 14 weeks...
2017: Journal of Pain Research
https://www.readbyqxmd.com/read/28905186/antidepressants-inhibit-nav1-3-nav1-7-and-nav1-8-neuronal-voltage-gated-sodium-channels-more-potently-than-nav1-2-and-nav1-6-channels-expressed-in-xenopus-oocytes
#2
Takafumi Horishita, Nobuyuki Yanagihara, Susumu Ueno, Dan Okura, Reiko Horishita, Tomoko Minami, Yuichi Ogata, Yuka Sudo, Yasuhito Uezono, Takeyoshi Sata, Takashi Kawasaki
Tricyclic antidepressants (TCAs) and duloxetine are used to treat neuropathic pain. However, the mechanisms underlying their analgesic effects remain unclear. Although many investigators have shown inhibitory effects of antidepressants on voltage-gated sodium channels (Nav) as a possible mechanism of analgesia, to our knowledge, no one has compared effects on the diverse variety of sodium channel α subunits. We investigated the effects of antidepressants on sodium currents in Xenopus oocytes expressing Nav1...
September 14, 2017: Naunyn-Schmiedeberg's Archives of Pharmacology
https://www.readbyqxmd.com/read/28894590/trpa1-channel-mediates-organophosphate-induced-delayed-neuropathy
#3
Qiang Ding, Sui Fang, Xueqin Chen, Youxin Wang, Jian Li, Fuyun Tian, Xiang Xu, Bernard Attali, Xin Xie, Zhaobing Gao
The organophosphate-induced delayed neuropathy (OPIDN), often leads to paresthesias, ataxia and paralysis, occurs in the late-stage of acute poisoning or after repeated exposures to organophosphate (OP) insecticides or nerve agents, and may contribute to the Gulf War Syndrome. The acute phase of OP poisoning is often attributed to acetylcholinesterase inhibition. However, the underlying mechanism for the delayed neuropathy remains unknown and no treatment is available. Here we demonstrate that TRPA1 channel (Transient receptor potential cation channel, member A1) mediates OPIDN...
2017: Cell Discovery
https://www.readbyqxmd.com/read/28893757/effectiveness-and-cost-effectiveness-of-duloxetine-added-to-usual-care-for-patients-with-chronic-pain-due-to-hip-or-knee-osteoarthritis-protocol-of-a-pragmatic-open-label-cluster-randomised-trial-the-duo-trial
#4
Jacoline J van den Driest, Dieuwke Schiphof, Pim A J Luijsterburg, Aafke R Koffeman, Marc A Koopmanschap, Patrick J E Bindels, Sita M A Bierma-Zeinstra
INTRODUCTION: Osteoarthritis (OA) is a highly prevalent painful condition of the musculoskeletal system. The effectiveness of current analgesic options has proven to be limited and improved analgesic treatment is needed. Several randomised placebo-controlled trials have now demonstrated the efficacy of duloxetine, an antidepressant with a centrally acting effect, in the treatment of OA pain. The aim of the current study is to investigate if duloxetine is effective and cost-effective as a third-choice analgesic added to usual care for treating chronic pain compared with usual care alone in general practice...
September 11, 2017: BMJ Open
https://www.readbyqxmd.com/read/28859883/analgesic-effects-of-novel-lysophosphatidic-acid-receptor-5-antagonist-as2717638-in-rodents
#5
Nobuhito Murai, Hideki Hiyama, Tetsuo Kiso, Toshihiro Sekizawa, Tomonari Watabiki, Hiromasa Oka, Toshiaki Aoki
Lysophosphatidic acid (LPA) is a bioactive lipid that acts via at least six G protein-coupled receptors, LPA receptors 1-6 (LPA1-6), for various physiological functions. We examined (1) whether LPA5 is involved in pain signaling in the spinal cord; and (2) the pharmacological effects of a novel LPA5 antagonist on intrathecal prostaglandin (PG)- and (S)-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-induced allodynia, and neuropathic and inflammatory pain in rodents. Intrathecal injection of a selective LPA5 agonist, geranylgeranyl diphosphate, and a non-selective agonist, LPA, induced allodynia in wild type, but not in LPA5 knockout mice...
August 30, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28851798/study-protocol-for-a-multi-institutional-randomised-double-blinded-placebo-controlled-phase-iii-trial-investigating-additive-efficacy-of-duloxetine-for-neuropathic-cancer-pain-refractory-to-opioids-and-gabapentinoids-the-direct-study
#6
Hiromichi Matsuoka, Hiroto Ishiki, Satoru Iwase, Atsuko Koyama, Takashi Kawaguchi, Yoshiyuki Kizawa, Tatsuya Morita, Yoshinobu Matsuda, Tempei Miyaji, Keisuke Ariyoshi, Takuhiro Yamaguchi
INTRODUCTION: Management of patients with cancer suffering from neuropathic pain refractory to opioids and gabapentinoids remains an important challenge. Duloxetine is one of the choices after first-line treatment fails. The efficacy of duloxetine has been reported in patients with non-cancer disease and in chemotherapy-induced peripheral neuropathy, but no randomised clinical trials have examined its effects on neuropathic cancer pain refractory to first-line treatment. The objective of this study is to assess the analgesic efficacy of duloxetine in patients suffering from neuropathic cancer pain refractory to opioids and gabapentinoids...
August 28, 2017: BMJ Open
https://www.readbyqxmd.com/read/28833461/melatonin-limits-paclitaxel-induced-mitochondrial-dysfunction-in-vitro-and-protects-against-paclitaxel-induced-neuropathic-pain-in-the-rat
#7
Helen F Galley, Barry McCormick, Kirsten L Wilson, Damon A Lowes, Lesley Colvin, Carole Torsney
Chemotherapy-induced neuropathic pain is a debilitating and common side effect of cancer treatment. Mitochondrial dysfunction associated with oxidative stress in peripheral nerves has been implicated in the underlying mechanism. We investigated the potential of melatonin, a potent antioxidant that preferentially acts within mitochondria, to reduce mitochondrial damage and neuropathic pain resulting from the chemotherapeutic drug paclitaxel. In vitro, paclitaxel caused a 50% reduction of mitochondrial membrane potential and metabolic rate, independent of concentration (20-100μM)...
August 22, 2017: Journal of Pineal Research
https://www.readbyqxmd.com/read/28831260/an-observational-study-of-duloxetine-versus-ssri-monotherapy-in-japanese-patients-with-major-depressive-disorder-subgroup-analyses-of-treatment-effectiveness-for-pain-depressive-symptoms-and-quality-of-life
#8
Atsushi Kuga, Toshinaga Tsuji, Shinji Hayashi, Shinji Fujikoshi, Hirofumi Tokuoka, Aki Yoshikawa, Rodrigo Escobar, Kazuhide Tanaka, Takaharu Azekawa
OBJECTIVE: To examine how clinical and demographic patient baseline characteristics influence effectiveness of duloxetine versus selective serotonin reuptake inhibitor (SSRI) treatment, in real-world Japanese clinical settings of patients with major depressive disorder (MDD) and associated painful physical symptoms (PPS). METHODS: This was a multicenter, 12-week, prospective, observational study in patients with MDD (Quick Inventory of Depressive Symptomatology ≥16) and at least moderate PPS (Brief Pain Inventory-Short Form [BPI-SF] average pain ≥3)...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28831259/an-observational-study-of-duloxetine-versus-ssri-monotherapy-for-the-treatment-of-painful-physical-symptoms-in-japanese-patients-with-major-depressive-disorder-primary-analysis
#9
Atsushi Kuga, Toshinaga Tsuji, Shinji Hayashi, Mako Matsubara, Shinji Fujikoshi, Hirofumi Tokuoka, Aki Yoshikawa, Rodrigo Escobar, Kazuhide Tanaka, Takaharu Azekawa
OBJECTIVE: The objective of this study was to assess the effectiveness of duloxetine monotherapy, in comparison with selective serotonin reuptake inhibitor (SSRI) monotherapy, in the treatment of painful physical symptoms (PPS) in Japanese patients with major depressive disorder (MDD) in real-world clinical settings. METHODS: This was a multicenter, 12-week prospective, observational study. This study enrolled MDD patients with at least moderate PPS, defined as a Brief Pain Inventory-Short Form (BPI-SF) average pain score (item 5) ≥3...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28780039/disruption-of-5-ht2a-pdz-protein-interaction-differently-affects-the-analgesic-efficacy-of-ssri-snri-and-tca-in-the-treatment-of-traumatic-neuropathic-pain-in-rats
#10
Anne-Sophie Wattiez, Amandine Dupuis, Anne-Marie Privat, Maryse Chalus, Eric Chapuy, Youssef Aissouni, Alain Eschalier, Christine Courteix
Antidepressants remain one of the first line treatments prescribed to neuropathic pain patients despite their limited efficacy and/or their numerous side effects. More and more, pharmacotherapy for neuropathic pain has evolved towards the use of therapeutic combinations. The goal of the present study was to assess the efficacy of the combination of antidepressants - selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors-with a peptide (TAT-2ASCV) able to disrupt the interaction between serotonin type 2A (5-HT2A) receptors and associated PDZ proteins...
August 2, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28769859/adverse-effects-of-antidepressants-for-chronic-pain-a-systematic-review-and-meta-analysis
#11
Carina Riediger, Tibor Schuster, Kristian Barlinn, Sarah Maier, Jürgen Weitz, Timo Siepmann
BACKGROUND: Antidepressants are widely used in the treatment of chronic pain. Applied doses are lower than those needed to unfold an antidepressive effect. While efficacy of antidepressants for chronic pain has been reported in large randomized-controlled trials (RCT), there is inconsistent data on adverse effects and tolerability. We aimed at synthesizing data from RCT to explore adverse effect profiles and tolerability of antidepressants for treatment of chronic pain. METHODS: Systematic literature research and meta-analyses were performed regarding side effects and safety of different antidepressants in the treatment of chronic pain according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines...
2017: Frontiers in Neurology
https://www.readbyqxmd.com/read/28769588/duloxetine-60-mg-for-chronic-low-back-pain-post-hoc-responder-analysis-of-double-blind-placebo-controlled-trials
#12
Levent Alev, Shinji Fujikoshi, Aki Yoshikawa, Hiroyuki Enomoto, Mitsuhiro Ishida, Toshinaga Tsuji, Kei Ogawa, Shinichi Konno
INTRODUCTION: Duloxetine has demonstrated efficacy in chronic low back pain (CLBP). We examined the predictors of response to duloxetine for CLBP. PATIENTS AND METHODS: This was a post hoc analysis of pooled data from 4 double-blind, ran-domized, placebo-controlled trials of duloxetine (60 mg/day for 12-14 weeks) in adult patients with CLBP. Primary outcome was proportion of patients with ≥30% reduction in Brief Pain Inventory (BPI) average pain ("pain reduction") at 12-14 weeks...
2017: Journal of Pain Research
https://www.readbyqxmd.com/read/28764837/supportive-treatments-for-patients-with-cancer
#13
Karin Jordan, Petra Feyer, Ulrike Höller, Hartmut Link, Bernhard Wörmann, Franziska Jahn
BACKGROUND: For the treatment of patients with cancer to be successful and well-tolerated, the complications and side effects of the disease and its treatment must be treated and limited as far as possible. Summarized recommendations based on the constantly increasing evidence in the area of supportive care must be defined, standardized, and communicated. METHODS: We systematically reviewed the literature on the topics of anemia, neutropenia, nausea/vomiting, diarrhea, oral mucositis, skin toxicity, and peripheral neurotoxicity induced by cancer treatment, as well as osseous complications, extravasation, and side effects of radiotherapy...
July 10, 2017: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/28734941/sleep-chronic-pain-and-opioid-risk-for-apnea
#14
REVIEW
Serguei Marshansky, Pierre Mayer, Dorrie Rizzo, Marc Baltzan, Ronald Denis, Gilles J Lavigne
Pain is an unwelcome sleep partner. Pain tends to erode sleep quality and alter the sleep restorative process in vulnerable patients. It can contribute to next-day sleepiness and fatigue, affecting cognitive function. Chronic pain and the use of opioid medications can also complicate the management of sleep disorders such as insomnia (difficulty falling and/or staying asleep) and sleep-disordered breathing (sleep apnea). Sleep problems can be related to various types of pain, including sleep headache (hypnic headache, cluster headache, migraine) and morning headache (transient tension type secondary to sleep apnea or to sleep bruxism or tooth grinding) as well as periodic limb movements (leg and arm dysesthesia with pain)...
July 19, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28708674/chemotherapy-induced-peripheral-neuropathy-a-review-of-recent-findings
#15
Peggy Y Kim, Carrie E Johnson
PURPOSE OF REVIEW: Chemotherapy-induced peripheral neuropathy (CIPN) is a common, frequently chronic condition characterized by pain and decreased function. Given the growing number of cancer survivors and an increasing recognition of opioid therapy limitations, there is a need for critical analysis of the literature in directing an informed and thoughtful approach for the management of painful CIPN. RECENT FINDINGS: A PubMed search for 'chemotherapy-induced peripheral neuropathy AND pain' identifies 259 publications between 1 January 2016 and 31 March 2017...
October 2017: Current Opinion in Anaesthesiology
https://www.readbyqxmd.com/read/28676788/a-systematic-review-of-treatment-of-painful-diabetic-neuropathy-by-pain-phenotype-versus-treatment-based-on-medical-comorbidities
#16
Luiz Clemente Rolim, Edina M Koga da Silva, João Roberto De Sá, Sérgio Atala Dib
BACKGROUND: Painful diabetic neuropathy (PDN) is a serious, polymorphic, and prevalent complication of diabetes mellitus. Most PDN treatment guidelines recommend a selection of drugs based on patient comorbidities. Despite the large numbers of medications available, most randomized clinical trials (RCTs) conducted so far have yielded unsatisfactory outcomes. Therefore, treatment may require a personalized approach based on pain phenotype or comorbidities. METHODS: To evaluate whether or not a patient's pain phenotype or comorbidities can influence the response to a specific PDN treatment, we conducted a systematic review using two different approaches: pain phenotype and associated comorbidities-based treatment...
2017: Frontiers in Neurology
https://www.readbyqxmd.com/read/28655928/brain-activity-changes-in-a-macaque-model-of-oxaliplatin-induced-neuropathic-cold-hypersensitivity
#17
Kazuaki Nagasaka, Kazunori Yamanaka, Shinya Ogawa, Hiroyuki Takamatsu, Noriyuki Higo
The antineoplastic agent oxaliplatin induces a painful peripheral neuropathy characterized by an acute cold hypersensitivity. There is a lack of effective treatments to manage oxaliplatin-induced cold hypersensitivity which is due, in part, to a lack of understanding of the pathophysiology of oxaliplatin-induced cold hypersensitivity. Thus, brain activity in oxaliplatin-treated macaques was examined using functional magnetic resonance imaging (fMRI). Oxaliplatin treatment reduced tail withdrawal latency to a cold (10 °C) stimulus, indicating cold hypersensitivity and increased activation in the secondary somatosensory cortex (SII) and the anterior insular cortex (Ins) was observed...
June 27, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28652290/imaging-pain-relief-in-osteoarthritis-ipro-protocol-of-a-double-blind-randomised-controlled-mechanistic-study-assessing-pain-relief-and-prediction-of-duloxetine-treatment-outcome
#18
Diane Reckziegel, Helen Bailey, William J Cottam, Christopher R Tench, Ravi P Mahajan, David A Walsh, Roger D Knaggs, Dorothee P Auer
INTRODUCTION: Osteoarthritis (OA) pain is a major cause of long-term disability and chronic pain in the adult population. One in five patients does not receive satisfactory pain relief, which reflects the complexity of chronic pain and the current lack of understanding of mechanisms of chronic pain. Recently, duloxetine has demonstrated clinically relevant pain relief, but only in half of treated patients with OA. Here, the aim is to investigate the neural mechanisms of pain relief and neural signatures that may predict treatment response to duloxetine in chronic knee OA pain...
June 26, 2017: BMJ Open
https://www.readbyqxmd.com/read/28622208/duloxetine-plasma-concentrations-and-its-effectiveness-in-the-treatment-of-nonorganic-chronic-pain-in-the-orofacial-region
#19
Yuka Kobayashi, Wataru Nagashima, Tatsuya Tokura, Keizo Yoshida, Eri Umemura, Tomoya Miyauchi, Munetaka Arao, Mikiko Ito, Hiroyuki Kimura, Kenichi Kurita, Norio Ozaki
OBJECTIVE: The purpose of this study was to examine the relationship between the pain-relieving effects of duloxetine and its plasma concentrations in patients with burning mouth syndrome and atypical odontalgia characterized by chronic nonorganic pain in the orofacial region. METHODS: We administered duloxetine to 77 patients diagnosed as having burning mouth syndrome or atypical odontalgia for 12 weeks. The initial dose of duloxetine was established as 20 mg/d and was increased to 40 mg/d after week 2...
July 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/28615967/assessment-of-direct-analgesic-effect-of-duloxetine-for-chronic-low-back-pain-post-hoc-path-analysis-of-double-blind-placebo-controlled-studies
#20
Hiroyuki Enomoto, Shinji Fujikoshi, Jumpei Funai, Nao Sasaki, Michael H Ossipov, Toshinaga Tsuji, Levent Alev, Takahiro Ushida
BACKGROUND: Comorbid depression and depressive symptoms are common in patients with chronic low back pain (CLBP). Duloxetine is clinically effective in major depressive disorder and several chronic pain states, including CLBP. The objective of this post hoc meta-analysis was to assess direct and indirect analgesic efficacy of duloxetine for patients with CLBP in previous clinical trials. METHODS: Post hoc path analyses were conducted of 3 randomized, double-blind, clinical studies of patients receiving duloxetine or placebo for CLBP...
2017: Journal of Pain Research
keyword
keyword
75047
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"